加载中
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
收盘时
US$3.63
US$0.00 · 0.00%
盘后
US$3.63
US$0.00 · 0.00%
10月12日 16:00 ET
盘中时间采用ET。市场数据可能有所延迟。
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
日内区间
当前US$3.63
52周区间
当前US$3.63
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
17
估值过高
情绪
42
多空交织
风险
74
高风险
动量
33
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
日内区间
当前US$3.63
52周区间
当前US$3.63
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 490.4万 USD | 517.4万 USD | 452.9万 USD | 550.8万 USD | 447.4万 USD |
| 销货成本 | 153.1万 USD | 3442.6万 USD | 97.2万 USD | 3501.7万 USD | 2001.5万 USD |
| 毛利 | 337.3万 USD | −2925.2万 USD | 355.7万 USD | −2950.9万 USD | −1554.1万 USD |
| 研究与开发 | 2371.7万 USD | 3442.6万 USD | 3377万 USD | 3501.7万 USD | 2001.5万 USD |
| 销售、一般及管理费用 | 1240.9万 USD | 1318.4万 USD | 1067.7万 USD | 743.7万 USD | 828.1万 USD |
| 营业费用 | 3459.5万 USD | 1318.4万 USD | 4444.7万 USD | 743.7万 USD | 828.1万 USD |
| 利息收入 | 38.8万 USD | 69.7万 USD | 17.9万 USD | 2.9万 USD | 5000 USD |
| 利息支出 | 1659万 USD | 1074.2万 USD | 262.6万 USD | 2.9万 USD | 6.4万 USD |
| 折旧和摊销 | 153.1万 USD | 132.5万 USD | 97.2万 USD | 89.2万 USD | 116.9万 USD |
| 营业利润 | −3122.2万 USD | −4243.6万 USD | −4089万 USD | −3694.6万 USD | −2382.2万 USD |
| 净利润 | −1.74亿 USD | −1891.6万 USD | −6904.5万 USD | −3691.7万 USD | −2315.5万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$15.00
上涨空间 313.22%评级样本有限，仅4项
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2019年5月10日 | 1:14 | — | — |
股票拆分 | 2017年4月25日 | 1:10 | — | — |
股票拆分 | 2015年8月7日 | 1:50 | — | — |
股票拆分 | 2006年5月11日 | 1:10 | — | — |
已生效 2019年5月10日
1:14
已生效 2017年4月25日
1:10
已生效 2015年8月7日
1:50
已生效 2006年5月11日
1:10
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI192.63万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM72.52万0.00%787.4亿 USD0.19%US$277.88-0.38%
Vanguard Extended Market ETFVXF69.36万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO40.27万0.00%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO37.35万0.00%180亿 USD0.06%US$112.27-0.35%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM15万0.13%1.17亿 USD0.73%US$15.86-0.50%
iShares Micro-Cap ETFIWC13.67万0.01%13.17亿 USD0.60%US$181.66-0.73%
Vanguard Russell 2000 Growth ETFVTWG7.09万0.00%17亿 USD0.06%US$258.28-0.85%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
